Varagur Venkatesan
Papers
6
Total Citations
660
H-Index
5
About
Varagur Venkatesan is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the treatment landscape for oropharyngeal squamous cell carcinoma (OPSCC). His primary research focus is the comparative effectiveness of radiotherapy versus transoral robotic surgery (TORS) for early-stage disease, a debate he has addressed through the landmark ORATOR clinical trial program. As the principal investigator of the ORATOR phase II randomized trial, Venkatesan provided the first high-level evidence directly comparing these two curative-intent modalities. The seminal 2019 publication of the ORATOR results has been cited over 458 times, establishing a critical benchmark for shared decision-making. His subsequent work, including the final five-year outcomes published in 2024, continues to refine our understanding of survival, toxicity, and quality-of-life trade-offs. Beyond the ORATOR trial, Venkatesan has contributed to modern treatment outcomes using intensity-modulated radiation therapy and has led detailed sub-studies on swallowing physiology, ensuring that functional outcomes remain central to the conversation. His research is essential reading for any clinician or researcher navigating the evolving paradigm of de-escalation and personalized therapy in HPV-related oropharyngeal cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6